Type 2 Diabetes Trial, Recruiting (NCT06989008)

Type 2 Diabetes Trial, Recruiting NCT06989008 Sponsor: University of Illinois at Chicago Condition: Type 2 Diabetes

Printed from Voxsanity (voxsanity.com.au) — NCT06989008 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Type 2 Diabetes

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been diagnosed with type 2 diabetes and are between 18 and 65 years old.
People who live in one of these specific zip codes in the Chicago area: 60619, 60620, 60621, 60636, 60644, 60624, 60609, 60612, 60617, 60623, 60628, 60629, 60639, 60645, 60649, 60651, 60652, or 60653.
People who speak and understand English.
People who are willing to wear a continuous glucose monitor (a small sensor that tracks blood sugar) and a sports wristband during the study.
People who own a smartphone.

Who may not be able to join:

People for whom there are concerns about whether they can fully understand and agree to the study's consent process.
People who are unable to understand or are unwilling to follow the steps required by the research study.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 26 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Andy Boyd, MD, University of Illinois at Chicago

Phone: 312 771 6497

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06989008

Sponsor: University of Illinois at Chicago

Phase: Not Applicable

Status: Recruiting

Condition: Type 2 Diabetes

Trial contact: 312 771 6497

More information: https://clinicaltrials.gov/study/NCT06989008

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been diagnosed with type 2 diabetes and are between 18 and 65 years old.
People who live in one of these specific zip codes in the Chicago area: 60619, 60620, 60621, 60636, 60644, 60624, 60609, 60612, 60617, 60623, 60628, 60629, 60639, 60645, 60649, 60651, 60652, or 60653.
People who speak and understand English.
People who are willing to wear a continuous glucose monitor (a small sensor that tracks blood sugar) and a sports wristband during the study.
People who own a smartphone.

Who may not be able to join:

People for whom there are concerns about whether they can fully understand and agree to the study's consent process.
People who are unable to understand or are unwilling to follow the steps required by the research study.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 26 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

University of Illinois at Chicago

Registry

ClinicalTrials.gov

Start date

25 March 2025

Est. completion

1 January 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

The primary outcome is to collect and analyze continuous interstitial glucose measurements in 20 individuals with type 2 diabetes over a period of 20 days using a DEXCOM G7 continuous glucose monitor (CGM).

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov